Achieved Record Revenue for 2024 and Growth of 31%;Reduced 2024 Operational Cash Burn by 35% SOLANA BEACH, CALIFORNIA / ACCESS Newswire / February 26, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the ...
Gene expression changes were analyzed using RNA sequencing ... In the highly aggressive and fast-growing model, the ...
"We look forward to reporting topline data from the pivotal INFRONT-3 Phase 3 trial of latozinemab targeting frontotemporal dementia with a granulin gene mutation by the fourth quarter. Additionally, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback